IVA
NASDAQ · Healthcare · Biotechnology · FR
Next report
Analyst consensus
- Next report date
- Sep 25, 2026
- EPS estimate
- -$0.20
- Revenue estimate
- $6.3M
Latest reported
- Last report date
- Sep 25, 2025
- EPS actual
- -$1.89
- EPS estimate
- -$0.41
- Revenue actual
- $5.2M
- Revenue estimate
- $8.7M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -224.8%
- Revenue beats (12Q)
- 2
Q4 FY2025 · Mar 31, 2026
AI summary of management’s prepared remarks and analyst Q&A · For informational purposes only, not investment advice
Management highlights
Andrew mentioned that the global phase three clinical trial Native 3 completed enrollment in April 2025 and expects top - line readout in Q4 2026. In Q4 2025, Inventiva sold its global rights to Oda Parcel to Biasil. The company strengthened its leadership team. Jason updated on lanofibrinor's mechanism of action, development pathway, and the details of Native 3 trial
Guidance
Anticipates top - line readout of Native 3 trial in Q4 2026. Estimates cash runway extends to mid - Q1 2027 and mid - Q3 2027 assuming full exercise of Tranche 3 warrants
Segment performance
Not explicitly detailed in the provided transcript regarding absolute financial performance and revenue contribution % for each product segment
Risks & headwinds
Refer to SEC and AMF filings for discussion of associated risks
Analyst Q&A
Q: Can you update us on how the performance of the trial has been in terms of dropouts...
A: Seamus Fernandez's questions about trial dropouts, dose performance, and market interest were answered by Andrew and Jason.
Q: Native 3 is a very large data set...
A: Yasmin Rahimi's questions about biopsy sample analysis and safety monitoring were answered by Andrew and Jason.
Q: Drill down a little bit more upon final powering...
A: Ritu Barao's questions about trial powering and F3 diabetic population were answered by Jason.
Q: Follow up on that F4 population...
A: Thomas Smith's questions about F4 population were answered by Jason.
Q: On weight gain...
A: Michael Yee's questions about weight gain were answered by Jason.
Q: Follow - up to Richie's question...
A: Ellie Merla's questions about competitive data and undiagnosed MASH were answered by Andrew.
Q: Regarding the confirmatory trial...
A: Lucy Codrington's questions about confirmatory trial were answered by Jason.
Q: Around the use of background GLP - 1s...
A: Annabel Samimi's questions about GLP - 1 use and AIM - MASH tool were answered by Jason.
Q: Remind us of lanofibrinors FC and F2 versus F3 patients...
A: Rami Katsouda's questions about lanofibrinor in F2 and F3 patients were answered by Jason.
Q: Looking ahead a little bit in terms of the MASH guidelines...
A: Anna's questions about MASH guidelines and cash were answered by Andrew.
Q: Could you elaborate on your regulatory and commercial infrastructure...
A: Priscilla Hernandez's question about regulatory and commercial infrastructure was answered
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Sep 25, 2026